National Institute for Health Research: RECOVERY Trial Investigates Baricitinib as Potential COVID-19 Treatment
February 02, 2021
February 02, 2021
LONDON, England, Feb. 2 -- The National Institute for Health Research issued the following news:
The NIHR-supported RECOVERY trial has begun investigating the anti-inflammatory arthritis drug, baricitinib, as a potential treatment for hospitalised COVID-19 patients.
As an anti-inflammatory, baricitinib may block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state caused by severe COVID-19.
The researchers will inve . . .
The NIHR-supported RECOVERY trial has begun investigating the anti-inflammatory arthritis drug, baricitinib, as a potential treatment for hospitalised COVID-19 patients.
As an anti-inflammatory, baricitinib may block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state caused by severe COVID-19.
The researchers will inve . . .